Moderna Inc. began a Phase 1 human clinical trial of an mRNA vaccine targeting the Bundibugyo strain of Ebola virus on Aug. 4 [1, 2].
The trial is a critical response to a large outbreak of the virus currently occurring in the Democratic Republic of Congo. Developing a targeted vaccine for this specific strain is necessary to curb the spread of the disease and prevent further fatalities in the region [3, 4].
Health Canada has authorized the company to conduct the clinical trial within Canada [2, 5]. While the trial is being administered in Canada, the urgency of the research is driven by the escalating health crisis in the Democratic Republic of Congo [3, 5].
This study represents the first time the Bundibugyo-specific mRNA candidate has been tested in humans [1, 2]. The Phase 1 trial is designed to evaluate the initial safety and immunogenicity of the vaccine [1].
Moderna is utilizing the same messenger RNA technology that served as the foundation for its widely used COVID-19 vaccines to address this viral threat [1, 3]. The company is moving forward with the study as the outbreak in the Democratic Republic of Congo continues to prompt international health concerns [3].
“Moderna Inc. began a Phase 1 human clinical trial of an mRNA vaccine targeting the Bundibugyo strain of Ebola virus.”
The initiation of this trial signals a shift toward strain-specific mRNA responses for Ebola. Because different strains of Ebola can require different vaccine formulations, the ability to rapidly develop and test a Bundibugyo-specific candidate in Canada allows for a faster path toward deployment in the Democratic Republic of Congo, where the current outbreak is centered.
